ERBB2 and breast cancer: Treatment approaches for BC differ based on molecular characteristics, such as activation of the HER2, ER and PR hormonal receptors, gene mutations such as those in the BRCA1/2 and PIK3CA, and markers in the microenvironment of the immune system such as PDL1 and TIL.